XORTX Therapeutics Files 6-K with Financials
Ticker: XRTX · Form: 6-K · Filed: Aug 15, 2025 · CIK: 1729214
Sentiment: neutral
Topics: financials, reporting, sec-filing
TL;DR
XORTX dropped its Q2 financials, check the numbers.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on August 15, 2025, reporting for the period ending June 30, 2025. The filing includes condensed interim consolidated financial statements and management's discussion and analysis for the six months ended June 30, 2025. The company is based in Vancouver, Canada, and its CEO is Allen Davidoff.
Why It Matters
This filing provides investors with updated financial statements and management commentary, offering insights into the company's performance and financial health for the first half of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, XORTX faces inherent risks related to drug development, clinical trials, and regulatory approvals, which are not detailed in this specific filing but are typical for the industry.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- June 30, 2025 (date) — Reporting period end date
- August 15, 2025 (date) — Filing date
FAQ
What period do the financial statements in this 6-K cover?
The financial statements cover the three and six months ended June 30, 2025.
Who is the CEO of XORTX Therapeutics Inc. and when was this report signed?
Allen Davidoff is the Chief Executive Officer, and the report was signed on August 14, 2025.
What are the main exhibits included in this 6-K filing?
The main exhibits are the Condensed Interim Consolidated Financial Statements (99.1), Management Discussion and Analysis (99.2), CEO Certificate (99.3), and CFO Certificate (99.4).
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Where is XORTX Therapeutics Inc. located?
The company's business and mailing address is Suite 2400 - 745 Thurlow Street, Vancouver, BC, V6E 0C5.
Filing Stats: 165 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2025-08-15 09:29:44
Filing Documents
- f6k_081525.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 756KB
- exh_992.htm (EX-99.2) — 236KB
- exh_993.htm (EX-99.3) — 8KB
- exh_994.htm (EX-99.4) — 8KB
- logo.jpg (GRAPHIC) — 35KB
- 0001171843-25-005439.txt ( ) — 1064KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ⊠ Form 40-F □ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: August 14, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Condensed Interim Consolidated Financial Statements for the three and six months ended June 30, 2025 99.2 Management Discussion and Analysis for the six months ended June 30, 2025 99.3 CEO Certificate 99.4 CFO Certificate